J07BB
Influenza vaccines
Наименование на групата: WHO Collaborating Centre for Drug Statistics Methodology
Подгрупи
ATC класификацията е дърво. Тази категория се разделя на 2 подгрупи.
Лекарствени продукти в тази категория
19 продукта в тази категория и подгрупите ѝ.
| Търговско име | Концентрация |
|---|---|
| Adjupanrix | --¹ After mixing, 1 dose (0.5 ml) contains: Split influenza virus, inactivated, containing antigen* equivalent to: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14) 3.75 μg** * propagated in eggs ** haemagglutinin AS03 adjuvant composed of squalene (10.69 mg), DL-alfa-tocopherol (11.86 mg) and polysorbate 80 (4.86 mg) |
| Aflunov | --¹ Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: A/turkey/Turkey/1/2005 (H5N1) - like strain (NIBRG-23) (clade 2.2.1) 7.5 micrograms** per 0.5 ml dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** expressed in microgram haemagglutinin Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams |
| Celldemic | --¹ One dose (0.5 ml) contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of strain*: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) 7.5 micrograms** * propagated in Madin Darby Canine Kidney (MDCK) cells ** expressed in micrograms haemagglutinin. Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams |
| Efluelda | Efluelda suspеnsion for injection in pre-filled syringe |
| Efluelda Tetra | suspеnsion for injection in pre-filled syringe |
| Fluad | --¹ Each 0.5 ml dose contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains*: A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Missouri/11/2025, IVR-279) 15 micrograms HA** A/Darwin/1454/2025 (H3N2)-like strain (A/Michigan/105/2025, IVR-285) 15 micrograms HA** B/Tokyo/EIS13-175/2025-like strain (B/Tokyo/EIS13-175/2025, wild type) 15 micrograms HA** *propagated in fertilised hens’ eggs from healthy chicken flocks and adjuvanted with MF59C.1 **haemagglutinin |
| Fluarix Tetra | suspension for injection in pre-filled syringe |
| Flucelvax | --¹ Each 0.5 ml dose contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains*: A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Tasmania/318/2025, CVR-351) 15 micrograms HA** A/Darwin/1415/2025 (H3N2)-like strain (A/Tasmania/787/2025, CVR-388) 15 micrograms HA** B/Pennsylvania/14/2025-like strain (B/Arizona/21/2025, wild type) 15 micrograms HA** * propagated in Madin Darby Canine Kidney (MDCK) cells ** haemagglutinin |
| Fluenz | --¹ 1 dose (0.2 ml) contains: Reassortant influenza virus* (live attenuated) of the following three strains**: A/Missouri/11/2025 (H1N1) pdm09-like strain (A/Switzerland/6849/2025, MEDI 400592) 10⁷.⁰±⁰.⁵ FFU*** A/Darwin/1454/2025 (H3N2)-like strain (A/Darwin/1369/2025, MEDI 406666) 10⁷.⁰±⁰.⁵ FFU*** B/Tokyo/EIS13-175/2025-like strain (B/Perth/115/2025, MEDI 407730) 10⁷.⁰±⁰.⁵ FFU*** * Propagated in fertilised hens’ eggs from healthy chicken flocks. ** Produced in VERO cells by reverse genetic technology. This product contains genetically modified organisms (GMOs). *** Fluorescent Focus Units. |
| Foclivia | 15 µg/ml |
| Incellipan | --¹ One dose (0.5 ml) contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of strain*: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) 7.5 micrograms** * propagated in Madin Darby Canine Kidney (MDCK) cells ** expressed in micrograms haemagglutinin. Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams |
| Influvac | Influvac suspension for injection in pre-filled syringe |
| Influvac Tetra | suspension for injection in pre-filled syringe |
| Pandemic influenza vaccine H5N1 AstraZeneca | --¹ 1 dose (0.2 ml) contains: Reassortant influenza virus* (live attenuated) of the following strain***: A/Vietnam/1203/2004 (H5N1) strain (A/Vietnam/1203/2004, MEDI 0141000136) 10⁷.⁰±⁰.⁵ FFU** * propagated in fertilised hens’ eggs from healthy chicken flocks. ** produced in VERO cells by reverse genetic technology. This product contains a genetically modified organism (GMO). *** fluorescent focus units |
| Supemtek | --¹ One dose (0.5 ml) contains: Influenza virus haemagglutinin (HA) proteins, of the following strains*: A/California/07/2009 (H1N1)pdm09-like strain (A/California/07/2009) 45 micrograms HA A/Texas/50/2012 (H3N2)-like strain (A/Texas/50/2012) 45 micrograms HA B/Brisbane/60/2008-like strain (B/Brisbane/60/2008) 45 micrograms HA * produced by recombinant DNA technology using a baculovirus expression system in a continuous insect cell line that is derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda. |
| Supemtek Tetra | --¹ One dose (0.5 mL) contains: Influenza virus haemagglutinin (HA) proteins, of the following strains*: A/XXXXXX (H1N1).................................. 45 micrograms HA A/XXXXXX (H3N2).................................. 45 micrograms HA B/XXXXXX............................................... 45 micrograms HA B/XXXXXX............................................... 45 micrograms HA * produced by recombinant DNA technology using a baculovirus expression system in a continuous insect cell line that is derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda. |
| Vaxigrip | Vaxigrip suspеnsion for injection in pre-filled syringe |
| Vaxigrip Tetra | suspеnsion for injection in pre-filled syringe |
| Zoonotic Influenza Vaccine Seqirus | --¹ Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: A/Astrakhan/3212/2020 (H5N8) - like strain (CBER-RG8A) (clade 2.3.4.4b) 7.5 micrograms** per 0.5 ml dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** expressed in microgram haemagglutinin Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams |